Nycomed seeks EC approval of EX101 for osteoporosis

Nycomed (Zurich, Switzerland) submitted an MAA to the U.K.'s MHRA for EX101 to treat osteoporosis. The application was submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. The submission triggers an undisclosed milestone payment to EffRx Pharmaceuticals S.A. (Lausanne, Switzerland), which granted Nycomed exclusive rights to develop and commercialize the effervescent formulation of alendronate outside the U.S. and Japan. ...